• Explore /
  • Poster
  • / Combination between a long-acting engineered cytokine (NKTR-214) and checkpoint inhibitors anti-CTLA-4 or anti-PD1 in murine tumor models.

Combination between a long-acting engineered cytokine (NKTR-214) and checkpoint inhibitors anti-CTLA-4 or anti-PD1 in murine tumor models.

Abstract Poster

Authors

null

Seema S. Kantak

Nektar Therapeutics, San Francisco, CA

Seema S. Kantak , Steve Lee , Murali Addepalli , Ute Hoch , Rhoneil Pena , Yolanda Kirksey , Deborah H. Charych , Stephen K. Doberstein

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2014 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics - Immunotherapy

Track

Developmental Therapeutics

Sub Track

Immunotherapy and Biologic Therapy

Citation

J Clin Oncol 32:5s, 2014 (suppl; abstr 3082)

DOI

10.1200/jco.2014.32.15_suppl.3082

Abstract #

3082

Poster Bd #

149

Abstract Disclosures